Advances in PSMA-Targeted Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer.

Area of Science:

• Oncology
• Nuclear Medicine
• Urology

Background:

• Prostate cancer (PCa) remains a leading cause of cancer death in men.
• Despite advancements, treatment options for metastatic castrate-resistant prostate cancer (mCRPC) are limited.
• Radioisotopic therapies, particularly those targeting PSMA, have emerged as a promising treatment modality.

Purpose of the Study:

• To review the current clinical and preclinical landscape of PSMA-targeted therapies for prostate cancer.
• To evaluate the efficacy and safety of these novel treatments.
• To identify potential biomarkers for assessing therapeutic response and guiding treatment decisions.

Main Methods:

• Comprehensive literature search of preclinical studies and clinical trials involving PSMA-targeted therapies.
• Analysis of data on efficacy, safety, and patient outcomes.
• Review of biomarkers associated with PSMA expression and treatment response.

Main Results:

• Lutetium-177 (177Lu) PSMA therapy is FDA-approved for PSMA-positive mCRPC, demonstrating encouraging results.
• Numerous clinical trials are investigating PSMA-targeted therapies in various settings, including monotherapy and combination approaches.
• Potential biomarkers for evaluating therapeutic response are under investigation.

Conclusions:

• PSMA-targeted radioisotopic therapy represents a significant advancement in prostate cancer treatment.
• Further research is crucial to overcome existing limitations and mitigate long-term toxicities, such as nephrotoxicity.
• Careful patient selection and biomarker-guided approaches are essential for optimizing treatment outcomes.